Skip to main content
OpenTrials
Completed

NCT Number: NCT07211854

Antithrombotic Strategies in Coronary Artery Dilatations and Aneurysms

Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications.

Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier de Versailles

Le Chesnay, 78150, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient > 18 years old
  • Patient living or deceased
  • Patient with aneurysmal or ectatic coronary artery disease with bi- or tri-truncular involvement at coronary angiography.

Exclusion criteria

  • Patient < 18 years old
  • Monotruncal aneurysmal or ectatic disease
  • Absence of coronary aneurysm / ectasia
  • Patient's opposition to participation in research

Treatment and study plan

Anticoagulant Treatment

Other

Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.

Other names: Antiplatelet therapy

Primary outcomes

  1. The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date

    Time frame: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023

    The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations).

  2. The nature of antithrombotic treatments

    Time frame: Discharge from hospital (day 1)

    The nature of antithrombotic treatments

Secondary outcomes

  1. The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)

    Time frame: The follow-up period between 2013 and 2023

    The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)

  2. The occurrence of haemorrhagic events of any kind

    Time frame: The follow-up period between 2013 and 2025

    The occurrence of haemorrhagic events of any kind

Sponsors and collaborators

Lead sponsor

Franck Assayag

Other

Registry information

Acronym: ASCADA

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Oct 8, 2025
Registry last updated
Oct 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.